Medical diagnostics
Advances in disease detection can characterise all manner of health disorders with greater precision.
-
Produced with support from:
Working out what ails a person is a founding principle of modern medicine. And as treatments improve and become more tightly targeted, access to a precise and rapid diagnosis is more important than ever.
New technologies and techniques are enabling physicians and researchers to determine with great specificity what infection, malignancy, genetic condition or other malady is present. In some cases, they are speeding up the wait for results, and allowing diagnosis earlier in the disease course. Clearly, the world of medical diagnostics has entered a period of rapid change.
This collection will be updated throughout 2024, with reporting from journalists and research from across the Nature Portfolio journals. Follow Nature on X, Facebook and LinkedIn, and check back throughout the year to keep up with the latest additions.
Features
Original journalism from Nature.
AI's keen diagnostic eye
Powered by deep-learning algorithms, artificial intelligence systems could replace agents such as chemicals used to augment medical scans. By Neil Savage
18 April 2024
The future of at-home molecular testing
The COVID-19 pandemic showed what was possible for gene-based diagnostics. Now comes the true test - economics. By Elie Dolgin
21 March 2024
Tracking down tuberculosis
Improvements in screening and diagnosis could help to eradicate this curable disease. By Neil Savage
25 January 2024
Putting low-cost diagnostics to the test
Extending the 'good enough' approach used to detect COVID-19 to other illnesses could improve health care in low- and middle-income countries. By Michael Eisenstein
27 November 2023
Research and reviews
Curated from the Nature Portfolio journals.
Nature is pleased to acknowledge financial support from Seegene in producing this Outlook. Nature retains sole responsibility for all editorial content. About this content.
The supporting organization retains sole responsibility for the following message:
Seegene is a global molecular diagnostics company providing a total solution for healthcare through our unique, patented technology that combines high multiplex diagnostic assays with automatic testing systems.
Seegene’s syndromic PCR assays identify up to 15 targets with quantitative information in a single tube and have unprecedentedly enhanced sensitivity, specificity, and target coverage per test. Seegene OneSystem™ enables all Seegene’s syndromic PCR assays to be run in Seegene’s automated instrument, called ‘All-In-One System’ (AIOS). Eventually, all these assays can be also run in any scale of future AIOS.
Seegene’s OneSystem™ business makes our proprietary PCR technologies, resources, and know-how available to global partners who are willing to develop and commercialize new PCR assays. Scientists and experts in all fields around the world can develop syndromic PCR products addressing local needs with global partners under Seegene OneSystem™.
For this purpose, Seegene announces the ‘Open Innovation Program powered by Seegene’ in collaboration with Springer Nature.
The vision of Seegene is to take a step closer to a world free from all diseases and future pandemics through early syndromic PCR diagnosis in all fields.
SPONSOR FEATURES
Sponsor retains sole responsibility for the content of the below articles.
Why syndromic PCR technology is key to a pandemic-proof world
Polymerase chain reaction (PCR) testing, which played such a key role in tackling the COVID-19 pandemic, could be a critical technology for addressing future threats to human health.
Groundbreaking PCR technology to halt the spread of disease
The ability to check for many pathogens simply and simultaneously will make PCR tests more powerful than ever before, says a South Korean Company which is pursuing “molecular diagnostics for a world free from all disease”.
One-stop shop for multi-pathogen PCR testing is disease-detection game changer
A company in South Korea has embarked on a bold plan to consolidate the world’s PCR library resources into a single formidable system — and then collaborate with global experts to make syndromic PCR assays more accessible.
Built with Shorthand